Advertisement

PPIs as possible risk factor for copper deficiency myelopathy

Published:January 14, 2015DOI:https://doi.org/10.1016/j.jns.2015.01.009

      Highlights

      • A chronic and prolonged reduction of gastric acidity may impair copper absorption.
      • PPIs have already been significantly associated with vitamin B12 deficiency.
      • PPIs may contribute to copper deficiency.
      • The discontinuation of PPIs should be considered in patients with copper deficiency.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Verma R.
        • Praharaj H.N.
        • Khanna V.K.
        • Garg R.K.
        • Singh M.K.
        • Malhotra H.S.
        Study of micronutrients (copper, zinc and vitamin B12) in posterolateral myelopathies.
        J Neurol Sci. 2013; 329: 11-16https://doi.org/10.1016/j.jns.2013.03.004
        • Kumar N.
        Copper deficiency myelopathy (human swayback).
        Mayo Clin Proc. Oct. 2006; 81: 1371-1384
        • Kumar N.
        • Crum B.
        • Petersen R.C.
        • Vernino S.A.
        • Ahlskog J.E.
        Copper deficiency myelopathy.
        Arch Neurol. 2004; 61: 762-766
        • Jaiser S.R.
        • Winston G.P.
        Copper deficiency myelopathy.
        J Neurol. 2010; 257: 869-881
        • Plantone D.
        • Primiano G.
        • Renna R.
        • Restuccia D.
        • Iorio R.
        • Patanella K.A.
        • et al.
        Copper deficiency myelopathy: a report of two cases.
        J Spinal Cord Med. Oct. 24 2014; (http://dx.doi.org/10.1179/2045772314Y.0000000268 [Epub ahead of print])
        • Lee J.
        • Peña M.M.
        • Nose Y.
        • Thiele D.J.
        Biochemical characterization of the human copper transporter Ctr1.
        J Biol Chem. 2002; 277: 4380-4387
        • Horn J.
        The proton-pump inhibitors: similarities and differences.
        Clin Ther. 2000; 22 ([discussion 265]): 266-280
        • Kuipers E.J.
        Proton pump inhibitors and gastric neoplasia.
        Gut. 2006; 55: 1217-1221
        • Van Soest E.M.
        • Siersema P.D.
        • Dieleman J.P.
        • Sturkenboom M.C.
        • Kuipers E.J.
        Persistence and adherence to proton pump inhibitors in daily clinical practice.
        Aliment Pharmacol Ther. 2006; 24: 377-385
        • Lam J.R.
        • Schneider J.L.
        • Zhao W.
        • Corley D.A.
        Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
        JAMA. 2013; 310: 2435-2442https://doi.org/10.1001/jama.2013.280490